ArticleJournal of human hypertension2007
Plasma levels of complement C3 is associated with development of hypertension: a longitudinal cohort study.
Article in Journal of human hypertension, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 92 citations in OpenAlex.
- Association of LDL protein cargo with segmental pulse wave velocity in older adults in the atherosclerosis risk in communities study.Frontiers in aging · 2026Article
- Innate immunity and hypertension: unveiling inflammatory pathways for novel therapies.Frontiers in pharmacology · 2026Review
- Complement C3 in panvascular disease: a central integrator of immune signaling and vascular remodeling.Clinical science (London, England : 1979) · 2025Review
- Functional Roles of the Complement Immune System in Cardiac Inflammation and Hypertrophy.International journal of molecular sciences · 2025Review
- Cryo-EM analysis of complement C3 reveals a reversible major opening of the macroglobulin ring.Nature structural & molecular biology · 2025Article
- Association between circulatory complement activation and hypertensive renal damage: a case-control study.Renal failure · 2024Article
- Beneficial effects of Panax notoginseng (Burkill) F. H. Chen flower saponins in rats with metabolic hypertension by inhibiting the activation of the renin-angiotensin-aldosterone system through complement 3.BMC complementary medicine and therapies · 2023Article
- Exosome Proteomics Reveals the Deregulation of Coagulation, Complement and Lipid Metabolism Proteins in Gestational Diabetes Mellitus.Molecules (Basel, Switzerland) · 2022Article
- Immune system changes in those with hypertension when infected with SARS-CoV-2.Cellular immunology · 2022Review
- Sex and Age-Related Differences in Complement Factors Among Patients With Intermediate Age-Related Macular Degeneration.Translational vision science & technology · 2022Article
- The potential role of complement alternative pathway activation in hypertensive renal damage.Experimental biology and medicine (Maywood, N.J.) · 2022Article
- Structure-Guided Engineering of a Complement Component C3-Binding Nanobody Improves Specificity and Adds Cofactor Activity.Frontiers in immunology · 2022Article
- Potential Involvement of Complement Activation in Kidney Vascular Lesions of Arterionephrosclerosis.Frontiers in medicine · 2022Article
- Beyond Systemic Lupus Erythematosus and Anti-Phospholipid Syndrome: The Relevance of Complement From Pathogenesis to Pregnancy Outcome in Other Systemic Rheumatologic Diseases.Frontiers in pharmacology · 2022Review
- Exploring the Relationship of Perivascular Adipose Tissue Inflammation and the Development of Vascular Pathologies.Mediators of inflammation · 2022Review
- Association of Complement C3 with Clinical Deterioration Among Hospitalized Patients with COVID-19.International journal of general medicine · 2022Article
- The Complement System in Metabolic-Associated Kidney Diseases.Frontiers in immunology · 2022Review
- Autoimmune-mediated renal disease and hypertension.Clinical science (London, England : 1979) · 2021Review
- Weight changes in hypertensive patients with phlegm-dampness syndrome: an integrated proteomics and metabolomics approach.Chinese medicine · 2021Article
- The role of complement in arterial hypertension and hypertensive end organ damage.British journal of pharmacology · 2021Review
Corrections and comments
- Commented on by
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension has been associated with raised plasma levels of complement factor 3 and 4 (C3 and C4). The nature of this association is unclear. This population-based longitudinal study explored whether C3 or C4 is associated with development of hypertension. Blood pressure and plasma levels of C3 and C4 were determined in 2178 healthy men, aged 35-50 years, initially without treatment for hypertension. Incidence of hypertension and blood pressure increase over 15.7 (+/-2.2) years follow-up was studied in relation to C3 and C4 at baseline. Among men with initially normal blood pressure (<160/95 mm Hg), incidence of hypertension (>or=160/95 mm Hg or treatment) was 32, 42, 37 and 47%, respectively, for men with C3 in the first, second, third and fourth quartile (trend: P=0.001). This relationship remained significant after adjustment for confounding factors. Among men without blood pressure treatment, systolic BP increase (mean+standard error, adjusted for age, initial blood pressure and follow-up time) was 17.5+0.8, 19.6+0.9, 19.8+0.8 and 20.8+0.8 mm Hg, respectively, in the C3 quartiles (trend: P=0.004). C3 was not associated diastolic blood pressure at follow-up. Although C4 was associated with blood pressure at the baseline examination, there was no relationship between C4 and development of hypertension or future blood pressure increase. It is concluded that C3 in plasma is associated with future blood pressure increase and development of hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.